ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
515 Views
Share
bearishBabytree Group
27 Oct 2018 16:59

Last Week in GER Research: A Dancing Tesla, Babytree, Mobvista, TuanChe and Pintec

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we recap on polarized Tesla Motors...

Logo
393 Views
Share
bearishTencent
20 Oct 2018 19:18

Last Week in GER Research: Tencent Backed IPOs, Niu, Innovent Biologics, Babytree and Fujifilm

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight a very differentiated...

Logo
653 Views
Share
16 Oct 2018 17:18

Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)

Innovent Biologics launched the institutional book building today and intends to raise USD 377 to USD 423 million, with an implied market...

Logo
401 Views
Share
15 Oct 2018 19:25

Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality

Innovent Biologics Inc (1641475D HK) launched its Hong Kong IPO today. The mid-point of Innovent's IPO price range of HK$12.50-14.00 per share...

Logo
686 Views
Share
x